Us Bancorp \De\ Celldex Therapeutics, Inc. Transaction History

Us Bancorp \De\

$74.1 Billion
Q1 2025

A detailed history of Us Bancorp \De\ transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 252 shares of CLDX stock, worth $5,113. This represents 0.0% of its overall portfolio holdings.

Number of Shares

252

Previous 509 50.49%

Holding current value

$5,113

Previous $12,000 66.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$18.15 - $27.6 $4,664 - $7,093	-257 Reduced 50.49%	252 $4,000
Q4 2024 Feb 05, 2025	SELL	$23.31 - $32.4 $4,032 - $5,605	-173 Reduced 25.37%	509 $12,000
Q3 2024 Oct 28, 2024	BUY	$32.06 - $44.56 $1,442 - $2,005	45 Added 7.06%	682 $23,000
Q2 2024 Aug 06, 2024	SELL	$32.76 - $42.56 $1,081 - $1,404	-33 Reduced 4.93%	637 $23,000
Q1 2024 May 07, 2024	BUY	$35.22 - $51.88 $2,500 - $3,683	71 Added 11.85%	670 $28,000
Q4 2023 Feb 09, 2024	BUY	$22.61 - $40.65 $10,852 - $19,512	480 Added 403.36%	599 $23,000
Q3 2023 Nov 03, 2023	SELL	$25.45 - $37.46 $5,853 - $8,615	-230 Reduced 65.9%	119 $3,000
Q2 2023 Aug 09, 2023	SELL	$30.29 - $38.28 $1,726 - $2,181	-57 Reduced 14.04%	349 $11,000
Q1 2021 Apr 28, 2021	BUY	$16.19 - $29.91 $809 - $1,495	50 Added 14.04%	406 $8,000
Q4 2020 Feb 04, 2021	BUY	$14.99 - $22.75 $5,336 - $8,099	356 New	356 $6,000
Q3 2020 Nov 10, 2020	SELL	$9.65 - $15.19 $57 - $91	-6 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$1.61 - $13.41 $9 - $80	6 New	6 $0

Others Institutions Holding CLDX

# of Institutions

198

Shares Held

58M

Call Options Held

960K

Put Options Held

675K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $949M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account